Cardiovascular Drugs Practice Questions

Q: What is the drug with the highest efficacy to increase plasma HDL?

Nicotinic acid (Niacin). ***Nicotinic acid (Niacin)*** - Niacin has the **highest efficacy** among lipid-lowering drugs in increasing **plasma HDL cholesterol** levels, often by 15-35%. - It works by reducing the **hepatic synthesis of VLDL** (and thus LDL) as well as increasing the half-life of HDL. *Ezetimibe (Zetia)* - Ezetimibe primarily acts by inhibiting the **absorption of cholesterol** from the intestine. - While it lowers LDL cholesterol, its effect on **increasing HDL** is modest at best, typically in the single digits. *Gemfibrozil (Lopid)* - Gemfibrozil is a **fibrate** that is best known for significantly lowering **triglycerides** and increasing HDL cholesterol modestly. - Its effects on HDL are generally **less robust** than those of niacin, usually in the range of 10-20%. *Rosuvastatin (Crestor)* - Rosuvastatin is a **statin**, which primarily works by inhibiting **HMG-CoA reductase**, leading to a significant reduction in LDL cholesterol. - While statins can cause a small increase in HDL, typically about 5-10%, this effect is **not its primary mechanism** of benefit nor its greatest strength compared to niacin.

Q: Drug not used in pulmonary hypertension is:

Alpha blocker. ***Alpha blocker*** - Alpha-blockers primarily cause **systemic vasodilation** [1] and are not indicated for the specific pulmonary vascular remodeling and vasoconstriction seen in pulmonary hypertension. [2] - Their use could lead to an undesirable drop in **systemic blood pressure** [3] without adequately addressing the pulmonary arterial pressure. *Calcium channel blocker* - **Calcium channel blockers** (namely **dihydropyridines** like nifedipine and amlodipine) are used in a small subset of pulmonary hypertension patients who are **vasoreactive** on acute testing. - They work by relaxing pulmonary arterial smooth muscle, reducing **pulmonary vascular resistance**. *Endothelin receptor antagonist* - **Endothelin receptor antagonists** (e.g., bosentan, ambrisentan) block the effects of **endothelin-1**, a potent vasoconstrictor and smooth muscle proliferator involved in pulmonary hypertension. - They improve hemodynamics, exercise capacity, and clinical outcomes by preventing **vasoconstriction** and **vascular remodeling**. *Prostacyclin* - **Prostacyclin analogs** (e.g., epoprostenol, treprostinil) are potent **vasodilators** and inhibitors of platelet aggregation. - They are highly effective in treating severe pulmonary hypertension by relaxing pulmonary arteries and preventing **thrombosis**.

Q: Digitalis acts in atrial fibrillation by

Increasing AV node refractoriness. ***Increasing AV node refractoriness*** - **Digitalis** (digoxin) primarily works in atrial fibrillation by **increasing the refractoriness** of the **AV node** through enhanced **vagal tone**. - This action slows the conduction of electrical impulses from the atria to the ventricles, thereby controlling the **ventricular rate** - which is the therapeutic goal in AF. - This is the **clinical mechanism** by which digitalis treats atrial fibrillation. *Decreasing atrial contractility* - Digitalis has **positive inotropic effects** (increases contractility), not negative. - It increases both atrial and ventricular contractility through increased intracellular calcium. - This option is incorrect as it contradicts the fundamental action of digitalis. *Inhibiting Na+ K+ ATPase pump* - While this is the **molecular mechanism** of digitalis at the cellular level, it is not the direct answer to how digitalis "acts in atrial fibrillation." - Na+/K+ ATPase inhibition → increased intracellular Na+ → decreased Na+/Ca2+ exchange → increased intracellular Ca2+ → positive inotropy. - The question asks about the **therapeutic action in AF**, which is controlling ventricular rate through AV nodal effects, not the underlying molecular mechanism. - This is a common distractor - students must distinguish between molecular mechanism and clinical therapeutic action. *Inhibiting Na+ H+ ATPase pump* - Digitalis **does not inhibit the Na+/H+ exchanger**. - This pump is primarily involved in **pH regulation** and is not a target of cardiac glycosides. - This option is completely incorrect.

Q: Which of the following is a contraindication for the use of digitalis?

WPW Syndrome. ***WPW Syndrome*** - In **WPW syndrome**, digitalis can **accelerate conduction** through the accessory pathway, leading to a rapid and potentially life-threatening ventricular response, especially during **atrial fibrillation**. - This can trigger **ventricular tachycardia** or **ventricular fibrillation** in patients with pre-excitation. - This is an **absolute contraindication** to digitalis use. *Acute rheumatic carditis* - Acute rheumatic carditis is a **relative contraindication** to digitalis due to increased risk of **digitalis toxicity** in inflamed myocardium. - The inflamed heart muscle is more **sensitive to arrhythmogenic effects** of digitalis. - However, **WPW syndrome is a more absolute contraindication** as the mechanism of harm is more predictable and severe. - If heart failure is present, digitalis may be used with **extreme caution** under close monitoring. *Thyrotoxicosis* - While digitalis may be used cautiously in patients with thyrotoxicosis experiencing **tachyarrhythmias** or heart failure, it's not an absolute contraindication. - Digitalis effectiveness is **reduced in hyperthyroid states**, often requiring higher doses. - The primary treatment for thyrotoxicosis is to manage the **hyperthyroid state**, which often resolves the cardiac symptoms. *Atrial fibrillation with rapid ventricular response* - Digitalis is often used to **slow the ventricular rate** in atrial fibrillation with a rapid ventricular response by **increasing vagal tone** and inhibiting the AV node. - This is a common **indication** for digitalis therapy, not a contraindication.

Q: Which of the following is the most effective medication for reducing proteinuria in diabetic patients?

Perindopril. ***Perindopril*** - **Perindopril** is an **ACE inhibitor**, which are cornerstone drugs for reducing **proteinuria** in diabetic patients by lowering intraglomerular pressure and reducing glomerular hyperfiltration. - ACE inhibitors like perindopril have been shown to slow the progression of **diabetic nephropathy** and improve renal outcomes beyond just their antihypertensive effects. *Chlorthalidone* - **Chlorthalidone** is a **thiazide-type diuretic** primarily used for hypertension management and edema. - While it lowers blood pressure, it does not have the specific renoprotective effects on **proteinuria** that ACE inhibitors possess in diabetic nephropathy. *Clonidine* - **Clonidine** is a **central alpha-2 adrenergic agonist** used for hypertension, but it does not specifically target the mechanisms of proteinuria. - It works by reducing sympathetic outflow from the central nervous system, which is distinct from the renal hemodynamic effects of ACE inhibitors. *Metoprolol* - **Metoprolol** is a **beta-blocker** primarily used for hypertension and cardiovascular conditions. - While it reduces blood pressure, it does not offer the same degree of proteinuria reduction or renoprotective benefits in diabetic nephropathy as ACE inhibitors.

Q: Hyperkalemia is associated with:

Angiotensin-converting enzyme (ACE) inhibitors. ***Angiotensin-converting enzyme (ACE) inhibitors*** - **ACE inhibitors** block the conversion of **angiotensin I to angiotensin II**, which reduces **aldosterone** secretion. - Reduced **aldosterone** leads to decreased **potassium excretion** in the kidneys, causing **potassium retention** and potentially **hyperkalemia**. - This is a well-known adverse effect, especially in patients with **renal impairment** or when combined with **potassium-sparing diuretics** or **potassium supplements**. *Thiazide diuretics (e.g., Chlorthalidone)* - **Thiazide diuretics** work by inhibiting the **sodium-chloride cotransporter** in the **distal convoluted tubule**, increasing sodium and water excretion. - This action typically leads to **hypokalemia** by increasing **potassium excretion**, not hyperkalemia. *Loop diuretics (e.g., Furosemide)* - **Loop diuretics** inhibit the **Na-K-2Cl cotransporter** in the **thick ascending limb of the loop of Henle**. - They are potent **potassium-wasting diuretics** that cause **hypokalemia** through increased renal potassium excretion, not hyperkalemia. *Antiarrhythmic agents (e.g., Amiodarone)* - **Amiodarone** is an antiarrhythmic agent that primarily acts by blocking **potassium channels** and has complex electrophysiological effects. - It is not directly associated with causing **hyperkalemia**; its primary electrolyte-related side effects involve thyroid function, not potassium homeostasis.

Q: All drugs decrease mortality in heart failure except:

Digoxin. ***Digoxin*** - **Digoxin** is known to improve symptoms and reduce hospitalizations in heart failure, but it has **not been shown to decrease mortality** in large clinical trials (DIG trial). - Its narrow **therapeutic window** and potential for toxicity, especially in patients with renal impairment, limit its use primarily to symptom management. *Metoprolol* - **Metoprolol succinate**, a beta-blocker, significantly reduces mortality and morbidity in patients with chronic heart failure with reduced ejection fraction (MERIT-HF trial) by blocking the deleterious effects of the sympathetic nervous system. - It works by reducing heart rate, myocardial oxygen demand, and cardiac remodeling. *Enalapril* - **Enalapril**, an ACE inhibitor, is a cornerstone medication in heart failure treatment due to its proven ability to reduce mortality, hospitalizations, and improve quality of life (CONSENSUS, SOLVD trials). - It works by blocking the **renin-angiotensin-aldosterone system**, leading to vasodilation, reduced preload and afterload, and prevention of cardiac remodeling. *Telmisartan* - **Telmisartan**, an ARB (angiotensin receptor blocker), is used as an alternative in heart failure patients who cannot tolerate ACE inhibitors due to side effects like cough. - ARBs as a class have shown mortality benefits in heart failure, acting by blocking the **angiotensin II type 1 receptor**, producing similar cardiovascular benefits to ACE inhibitors in terms of vasodilation and reduction in cardiac remodeling.

Q: Which calcium channel blocker is known to cause reflex tachycardia?

Nifedipine. ***Nifedipine*** - **Nifedipine** is a **dihydropyridine calcium channel blocker** that causes significant **peripheral vasodilation**. - This rapid drop in blood pressure activates the **baroreceptor reflex**, leading to an increase in heart rate (**reflex tachycardia**) to compensate. *Verapamil* - **Verapamil** is a **non-dihydropyridine calcium channel blocker** that acts on both vascular smooth muscle and cardiac conduction. - It has a direct negative chronotropic effect on the heart, which typically **prevents reflex tachycardia**. *Amlodipine* - **Amlodipine** is a **long-acting dihydropyridine calcium channel blocker** with a more gradual onset of action. - While it causes peripheral vasodilation, its **slow onset and prolonged duration** of action typically result in less pronounced or absent reflex tachycardia compared to nifedipine. *Diltiazem* - **Diltiazem** is a **non-dihydropyridine calcium channel blocker** with effects on both the heart and peripheral vasculature. - Similar to verapamil, its direct **negative chronotropic and dromotropic effects** on the heart prevent significant reflex tachycardia.

Q: Which of the following drugs lack vasodilatory properties but are effective in angina?

Metoprolol. ***Metoprolol*** - **Metoprolol** is a beta-blocker that reduces myocardial oxygen demand by decreasing heart rate, contractility, and blood pressure, without direct vasodilatory effects. - Its efficacy in angina is primarily due to these **cardiac depressant actions**, which relieve myocardial ischemia. *Isosorbide dinitrate* - **Isosorbide dinitrate** is a nitrate that works by releasing nitric oxide, leading to **venodilation** and **arterial dilation**, particularly reducing preload and improving coronary blood flow. - Its anti-anginal effect is directly linked to its **vasodilatory properties**. *Nifedipine* - **Nifedipine** is a dihydropyridine calcium channel blocker that produces potent **vasodilation** of both coronary and peripheral arteries. - Its primary mechanism of action in angina involves **reducing afterload** and improving coronary blood flow through vasodilation. *Verapamil* - **Verapamil** is a non-dihydropyridine calcium channel blocker that causes **coronary and peripheral vasodilation**, reducing afterload and improving myocardial perfusion. - While it also reduces heart rate and contractility, its direct **vasodilatory effects** contribute significantly to its anti-anginal action.

Question 1

What is the mechanism of action of Verapamil?

Accepted Answer

Inhibition of calcium ion influx through L-type calcium channels

Answer

Blocking membrane depolarisation

Answer

Stabilization of cardiac membrane potential

Answer

Inhibition of calcium-dependent action potentials

Question 2

What is the drug with the highest efficacy to increase plasma HDL?

Accepted Answer

Nicotinic acid (Niacin)

Answer

Ezetimibe (Zetia)

Answer

Gemfibrozil (Lopid)

Answer

Rosuvastatin (Crestor)

Question 3

Drug not used in pulmonary hypertension is:

Accepted Answer

Alpha blocker

Answer

Endothelin receptor antagonist

Answer

Prostacyclin

Answer

Calcium channel blocker

Question 4

Digitalis acts in atrial fibrillation by

Accepted Answer

Increasing AV node refractoriness

Answer

Decreasing atrial contractility

Answer

Inhibiting Na+ K+ ATPase pump

Answer

Inhibiting Na+ H+ ATPase pump

Question 5

Which of the following is a contraindication for the use of digitalis?

Accepted Answer

WPW Syndrome

Answer

Thyrotoxicosis

Answer

Acute rheumatic carditis

Answer

Atrial fibrillation with rapid ventricular response

Question 6

Which of the following is the most effective medication for reducing proteinuria in diabetic patients?

Accepted Answer

Perindopril

Answer

Clonidine

Answer

Chlorthalidone

Answer

Metoprolol

Question 7

Hyperkalemia is associated with:

Accepted Answer

Angiotensin-converting enzyme (ACE) inhibitors

Answer

Thiazide diuretics (e.g., Chlorthalidone)

Answer

Antiarrhythmic agents (e.g., Amiodarone)

Answer

Loop diuretics (e.g., Furosemide)

Question 8

All drugs decrease mortality in heart failure except:

Accepted Answer

Digoxin

Answer

Enalapril

Answer

Metoprolol

Answer

Telmisartan

Question 9

Which calcium channel blocker is known to cause reflex tachycardia?

Accepted Answer

Nifedipine

Answer

Verapamil

Answer

Amlodipine

Answer

Diltiazem

Question 10

Which of the following drugs lack vasodilatory properties but are effective in angina?

Accepted Answer

Metoprolol

Answer

Isosorbide dinitrate

Answer

Nifedipine

Answer

Verapamil

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?